Nikolaos Tezapsidis, PhD President & CEO and Chairman of the Board   Eugene Oliva, MBA CFO    George Perry, PhD               Dr. George Perry obtained his bachelor of arts in zoology with high honors from the University of California at Santa Barbara in 1974 and completed his Ph.D. in marine biology from the Scripps Institution of Oceanography, University of California, San Diego in 1979.  After postdoctoral studies in cell biology at Baylor College of Medicine, Dr. Perry joined the faculty of Case Western Reserve University in 1982 as an Assistant Professor and served as a Professor in the Departments of Pathology and Neurosciences and as Interim-Chair of the Department of Pathology.  Additionally, he was named Fellow by the American Association for the Advancement of Science in 1998 and is an internationally known invited lecturer and has numerous papers, presentations and publications.  Dr. Perry is currently Dean of the College of Sciences at The University of Texas at San Antonio.             Dr. Perry’s studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer disease.  Dr. Perry’s group has shown that oxidative damage is the initial cytopathological abnormality in Alzheimer disease.  The lab is working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals.  Current studies focus on three issues: (i) the metabolic basis for the mitochondrial damage restricted to vulnerable neurons; (ii) the consequences of RNA oxidation on protein synthesis rate and fidelity; and (iii) role of phosphorylation in controlling oxidative adduction. Perry is among the top dozen most cited investigators studying AD/oxidative stress (over 2000 citations per year), and among the top 50 neuroscientists in the world.             Perry is a Fellow of the American Association for the Advancement of Sciences, recently won the Denham Harmon Lifetime Achievement Award (discoverer of the Free Radical Theory of Aging) from the American Association for Aging, and currently holds the Zenith Award from the Alzheimer Association.     James Harris, MBA         Mr Harris is CEO of Healthcare Economics LLC and co-founder of AS Biotech AG.  Prior to this he served as Vice President at Dragon Pharmaceuticals, Inc. where he was instrumental in the launch and successful market penetration of rh-Erythropoietin (“EPO") in non patented markets and is very well experienced in in-out licensing and business development internationally.  Before joining Dragon Mr. Harris was at Amgen where he held various positions of increasing responsibility.  He contributed in the product launches of EPO (Epogen®), GCSF (Neupogen®) at Amgen, and Intravenous Immune Globulin, IVIG (Gamimune®) at Bayer AG.  Mr. Harris has participated extensively as a featured speaker at medical meetings as well as authoring “GCSF and Bioequivalence: “The Emergence of Healthcare Economics” WILEY-VCH, Weinheim, Germany and “Marketing and Globalizing Biosimilars” Journal of Generic Medicines, London, UK.  He has served as the Assistant Area Chair Department of Graduate Business and Management at the University of Phoenix. Mr. Harris obtained a B.A. in Political Science from Wright State University and an M.B.A. in Finance from Long Island University.